Search Our Site

News filed in:

"Press Release"

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies The pharmaceutical company Insys Therapeutics has been in the news a lot recently—and for all the wrong reasons. Last September AMS reported about Insys’ schemes to sell more of their pain drug Subsys to unwitting physicians. Now, it seems that Insys didn’t just… Read More »

[...]

Read More

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies Spinal cord stimulation (SCS) is a pain-relief technique that continuously delivers a low-voltage electrical current to the spinal cord to block the sensation of pain. SCS is the most commonly used implantable neurostimulation technology for management of pain syndromes. As many as 50,000… Read More »

[...]

Read More

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies Specialty drugs continue to outpace traditional brand-name pharmaceuticals and generics, both in percentage of growth and absolute costs. In 1990 there were 10 specialty drugs on the market. By the mid-1990s, about 30. In 2015, 300. That year the average annual price of… Read More »

[...]

Read More

Advanced Medical Strategies (AMS) is pleased to release our 4th annual Top 5 list of the most commonly researched specialty drugs of 2017.   For the PredictRx Top 5 Researched Drugs of 2017, Remicade again tops the list as the one AMS clients inquired about the most during the past 12 months. Industry professionals should… Read More »

[...]

Read More

Advanced Medical Strategies Makes Inc. 5000 List of America’s Fastest-Growing Companies

LYNNFIELD, Mass — August 21, 2017— Advanced Medical Strategies (AMS), an industry leader in delivering technology-driven solutions for payment integrity, risk management, and high dollar claims issues, is proud to announce that it has been officially recognized by Inc. as one of America’s fasting growing private companies. The annual Inc. 5000 is ranked according to... Read More »

Read More →

LYNNFIELD, Mass — August 21, 2017— Advanced Medical Strategies (AMS), an industry leader in delivering technology-driven solutions for payment integrity, risk management, and high dollar claims issues, is proud to announce that it has been officially recognized by Inc. as one of America’s fasting growing private companies. The annual Inc. 5000 is ranked according to… Read More »

[...]

Read More

Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review, and that the company’s Marketing Authorization Application (MAA) has been validated by the European Medicines Agency (EMA). Nusinersen had previously... Read More »

Read More →

Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review, and that the company’s Marketing Authorization Application (MAA) has been validated by the European Medicines Agency (EMA). Nusinersen had previously… Read More »

[...]

Read More

FDA approves brain implant to help reduce Parkinson’s disease and essential tremor symptoms

Originally posted on: FDA.gov The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when... Read More »

Read More →

Originally posted on: FDA.gov The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when… Read More »

[...]

Read More

Originally posted on FDA.gov Release Today the U.S. Food and Drug Administration approved the Senza spinal cord stimulation (SCS) system (Senza System) as an aid in the management of chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, low back pain and leg pain. The Senza System can… Read More »

[...]

Read More

Originally posted on Express Scripts U.S. Prescription Drug Spending Increased 13.1 Percent in 2014, Driven by Hepatitis C and Compounded Medications The 2014 Express Scripts Drug Trend Report shows highest national spend increase over past decade. Excluding hepatitis C and compounded medications, drug spending increased 6.4 percent in 2014 More than 15 percent of Express… Read More »

[...]

Read More
Categories
Archives